



attana

life science and diagnostics

Attana has signed a collaborative research agreement with a leading US academic medical center for biomedical research

Attana can today announce that a collaborative research agreement has been signed with one of the leading US academic medical centers for biomedical research.

Attana AB has today signed a collaborative research agreement with one of the leading US academic medical centers within biomedical research, focusing on viruses and antibodies. Under the terms of the agreement, Attana will appoint personnel and an Attana Cell™ 250 instrument in the United States during Q1. The initial project scope will be performed through mid-June 2022 and can be mutually extended until the end of 2025. The aim of the collaboration is to jointly identify and develop unique research tools for the R&D of novel vaccines and therapeutic antibodies, based on Attana's technology and expertise. The order will affect Attana's cash flow and earnings in Q1 and Q2 of 2022.

Attana's CEO, Teodor Aastrup comments:

"We are very proud to initiate this project as it is aligned to our unique expertise and product offering. Additionally, the collaboration has the added benefit and potential to contribute to the positive development of both our business units – Life Science and Diagnostics."

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00

This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.

About Attana

Attana was founded in 2002 with the vision of *in vitro* characterization of molecular interactions mimicking *in vivo* conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary *in vitro* diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com